痰热清注射液联合胸腺肽α1治疗慢性阻塞性肺疾病急性加重期临床研究

Clinical Study on Tanreqing Injection Combined with Thymosinα1 for Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的:观察痰热清注射液联合胸腺肽α1治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床疗效。方法:选择92例AECOPD患者,按随机数字表法分为对照组与观察组各46例。对照组给予常规治疗,观察组在常规治疗的基础上加用痰热清注射液联合胸腺肽α1治疗。比较2组临床疗效、免疫功能、炎症标志物、肺功能、动脉血气分析指标及不良反应发生情况。结果:治疗后,观察组总有效率93.48%,高于对照组78.26%(P<0.05)。与同组治疗前比较,治疗后2组降钙素原(PCT)、C-反应蛋白(CRP)、白细胞计数(WBC)、肿瘤坏死因子-α(TNF-α)、CD8^(+)、二氧化碳分压(PaCO_(2))水平均降低(P<0.05),CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、动脉血氧分压(PaO_(2))、用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC水平均升高(P<0.05);与对照组治疗后比较,观察组治疗后PCT、CRP、TNF-α、WBC、CD8^(+)、PaCO_(2)水平均较低(P<0.05),CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、PaO_(2)、FEV1、FVC、FEV1/FVC水平均较高(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:采用痰热清注射液联合胸腺肽α1治疗AECOPD患者能有效减轻患者炎症反应,提高免疫功能,改善动脉血气指标及肺功能。

Objective:To observe the clinical effect of the therapy of Tanreqing injection combined with thymosinα1 on patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:A total of 92 patients with AECOPD were selected and divided into the control group and the observation group according to the random number table method,with 46 cases in each group.The control group was given routine treatment,and the observation group was additionally given Tanreqing injection combined with thymosinα1 based on the routine treatment.The clinical effects,immune function,inflammatory markers,the lung function,indexes of arterial blood gas analysis and adverse reactions in the two groups were compared.Results:After treatment,the total effective rate was 93.48%in the observation group,higher than that of 78.26%in the control group(P<0.05).After treatment,the levels of procalcitonin(PCT),C-reactive protein(CRP),white blood count(WBC),tumor necrosis factor-α(TNF-α),CD8^(+),and partial pressure of carbon dioxide(PaCO_(2))in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),arterial partial pressure of oxygen(PaO_(2)),forced vital capacity(FVC),forced expiratory volume in the one second(FEV1),and FEV1/FVC were increased(P<0.05);the levels of PCT,CRP,TNF-α,WBC,CD8^(+)and PaCO_(2) in the observation group were lower than those in the control group(P<0.05),and the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),PaO_(2),FEV1,FVC and FEV1/FVC were higher(P<0.05).There was no significant difference being found in the comparison of incidence of adverse reactions between the two groups(P>0.05).Conclusion:The therapy of Tanreqing injection combined with thymosinα1 for patients with AECOPD can effectively reduce the inflammatory responses and improve the immune function,index of arterial blood gas and the lung function.